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ALWI’RACT 
Objective: To evaluate the propensity of lincomycin and clin- 
damycin to induce release of endotoxin, the authors investigated 
endotoxin release in Escherichia co/i isolated from a patient who 
developed septic shock following lincomycin treatment, 
Methods: Endotoxin release from the E. co/i isolate exposed to 
lincomycin, clindamycin, and ceftazidime were determined in 
vitro and in vivo. 
Results: In vitro, this E. co/i released significantly larger amounts 
of endotoxin after exposure for 6 hours to lincomycin or clin- 
damycin versus no antibiotic; however, endotoxin release with 
these antibiotics was significantly less than with ceftazidime. 
There was no significant difference in in vitro endotoxin release 
between small (8 mg/L) and large (0.5 minimum inhibitory con- 
centration [MIC]) doses of these antibiotics, and 0.5 MlCs of 
lincomycin and clindamycin were 1024 and 256 mg/L, respec- 
tively. These results were supported by scanning electron 
microscopic observations, which demonstrated that lincomycin, 
clindamycin, and ceftazidime induced formation of filamentous 
cells. In addition, plasma endotoxin concentrations after treat- 
ment for 4 hours with lincomycin, clindamycin, and ceftazidime 
(5 mg/kg) were at least 20-fold higher than with no antibiotic 
in an E. co/i sepsis rat model. 
Conclusion: Results of this study suggest that the bacterio- 
static antibiotics, lincomycin and clindamycin, induce endo- 
toxin release in the treatment of E. co/i infections. 
Key Words: antibiotic-induced, clindamycin, endofoxin 
release, lincomycin, morphology sepsis 
Int J Infect Dis 2000; 4:118-122. 
*Department of Internal Medicine, Tsushima Chuoh Hospital, Tsushima, 
Japan; +Department of Bacteriology, Nagoya University School of Med- 
icine, Nagoya, Japan; *Laboratory of Clinical Pharmacology and Thera- 
peutics, Gifu Pharmaceutical University, Gii, Japan; and §Department of 
Anatomy, Nagoya University School of Medicine, Nagoya, Japan. 
Supported in part by a Grant-in-Aid for scientific research (11770138) 
from the Ministry of Education, Science, and CuIture,Japan. 
Received: November 29,1998;Accepted:April5,1999. 
Address correspondence to Dr.Toshinobu Horii, Department of Internal 
Medicine, Tsushima Chuoh Hospital, 63 Aza-Watagake, Hagari-cho, 
Tsushima 4960009, Japan. E-mail:horii@tsuru.med.nagoya-u.ac.jp. 
118 
Gram-negative sepsis is a dynamic clinical syndrome, 
defined by three stages: bacterial infection, systemic 
inflammation, and organ failure. l Endotoxin (lipopolysac- 
charide [LPS]) from gram-negative bacteria has been 
implicated as the primary initiating agent in gram-nega- 
tive sepsis, and in causing the clinical manifestations of 
septic shock.2 Antibiotic therapy is an early step in the 
treatment of gram-negative sepsis. However, exposure of 
gram-negative bacteria to antibiotics can increase the 
amount of endotoxin released, both in vitro and in vivo.3,* 
In vivo studies have suggested that antibiotic therapy for 
gram-negative bacteremia may be associated with wors- 
ening clinical symptoms.3-s 
A number of studies have characterized antibiotic- 
induced endotoxin release from gram-negative bacte- 
ria.5,s-18 Some reports have shown a correlation between 
endotoxin release and resulting morphologic changes in 
cells.7,14,16,1s In addition, the propensity to release endo- 
toxin depends on the mode of antibacterial action; 
cephalosporins, monobactams, aminoglycosides, quino- 
lones, and chloramphenicol generally cause release of 
large amounts of endotoxin from gram-negative bacilli, 
whereas carbapenems, such as imipenem and panipenem, 
release only small amounts. L1,‘3~16,18 However, to date, few 
studies on antibiotic-induced endotoxin release have 
focused on macrolides, lincomycin or clindamycin. 3 
To evaluate the propensity of lincomycin and clin- 
damycin to induce release of endotoxin, the authors 
investigated endotoxin release in Escherichia coli iso- 
lated from a patient who developed septic shock fol- 
lowing lincomycin treatment. 
PATIENT AND METHODS 
Patient 
Escherichiu coli TCH97-9379 strain was isolated from a 
blood sample of a patient who presented with clinical 
symptoms of septic shock 60 minutes after intravenous 
administration of lincomycin. Five-milliliter samples of 
blood were collected immediately before intravenous 
administration of imipenem, and this strain was isolated 
solely from the blood sample. The serotype of E. coli 
TCH97-9379 was 06:NM (nonmotile), and the phenotype 
was smooth LPS. The plasma endotoxin concentrations 
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were 5.4 rig/L by a chromogenic endotoxin-specific 
assay, using Limulus coagulation enzyme (ES test, Seika- 
gaku-Kogyo, Tokyo, Japan). Thereafter, blood samples 
were assayed until no bacteria were detectable. Bacteria 
were stored at -70°C in Luria-Bertani (LB) broth (Becton- 
Dickinson Japan, Tokyo, Japan) containing 20% glycerol. 
Subsequently, bacteria were inoculated on LB agar plates 
and incubated at 37°C overnight. 
Antibiotics 
The antibiotics used were ceftazidime (Japan Glaxo, 
Tokyo, Japan), clindamycin, and lincomycin (Pharmacia 
and Upjohn, Tokyo, Japan). 
Susceptibility Testing 
Minimum inhibitory concentrations (MICs) were deter- 
mined by an agar dilution method as described by the 
National Committee for Clinical Laboratory Standards.” 
Susceptibility testing was performed on Mueller-Hinton 
agar (Becton-Dickinson Japan), in accordance with the 
manufacturer’s instructions. 
Scanning Electron Microscopy 
The E. coli TCH97-9379 isolate on Mueller-Hinton agar 
was exposed for 3 hours to antibiotics, and morphology 
was examined by scanning electron microscopy (SEM) as 
follows. Bacteria were fured with Karnovsky’s fixative at 
4°C for 16 hours, stained with 1% osmium tetroxide and 
1% tannic acid, then dehydrated for 15 minutes each in 
increasing concentrations of ethanol (70%, SO%, 90%, 95%, 
and lOO%>, followed by isoamyl acetate (100%) for 15 
minutes. Samples were critical-point dried (HCP-2 critical 
point dryer, Hitachi, Tokyo, Japan), carbon-coated (JEE- 
450D, Jeol, Akishima, Japan) for 5 seconds, and platinum- 
coated with Ion Coating IB-2 (Eiko Engineering, 
Hitachinaka, Japan) for 3 minutes. Finally, specimens were 
examined with a Hitachi S-800 electron microscope at 
an accelerating voltage of 10 kV 
In Vitro Studies of Endotoxin Release 
Glass test tubes were rendered endotoxin-free by heating 
them at 250°C for 3 hours. Sterile, endotoxin-free plastic- 
ware (specimen containers and pipette tips) was used 
for all endotoxin assays. Bacteria were inoculated into 
Mueller-Hinton broth (5 mL) and incubated at 37°C for 
5 hours. Cultures were then diluted lOOO-fold in fresh 
Mueller-Hinton broth (10 mL) and incubated at 37°C for 
an additional 1.5, 3, or 6 hours in the presence of 0.5 
MIC or 8 mg/L of antibiotic. At each time-point, an aliquot 
was taken from the same bacterial culture. Three separate 
experiments were performed. The amount of free LPS in 
samples was determined after removing bacterium-bound 
LPS by filtration through an endotoxin-free 0.45~p,m pore 
cellulose ester filter (Millex-HA, Millipore, Tokyo, Japan).” 
The filtrates were immediately stored at -70°C. To quan- 
tify bacteria, aliquots of samples were then serially diluted 
in phosphate-buffered saline (PBS), pH 7.4, and 0.1 mL 
from each dilution was plated onto Mueller-Hinton agar. 
After overnight incubation at 37°C the number of colony- 
forming units (cfu) per milliliter was counted. 
In Vivo Studies of Endotoxin Release 
Male Wistar rats (225-235 g), purchased from Japan SLC 
(Hamamatsu, Japan), were challenged with an intraperi- 
toneal inoculation of lo6 cfu of the E. coli TCH97-9379 iso 
late. After 24 hour, the rats were given an intravenous dose 
of lincomycin (5 mg/kg), clindamycin (5 mg/kg), or cef- 
tazidime (5 mg/kg). Saline solution was used for the con- 
trol. There was no mortality within 24 hours of the study 
At 28 hours, blood (lo-12 mL) was drawn by aortic punc- 
ture under anesthesia, using diethyl ether, for endotoxin 
assay, complete blood count (CBC), and biochemical 
assays. Blood samples were collected in endotoxin-free 
glass test tubes. An aliquot of each blood sample was used 
for determination of the CBC (Sysmex K-800, Toa-Iyo-Den- 
shi, Kobe, Japan) and quantitative bacteriology, and the 
plasma was immediately prepared at 4°C by centrifugation 
at 800 g for 10 minutes. All samples were stored at -70°C 
until analysis. The plasma levels of glutamic-oxaloacetic 
transaminase (GOT), glutamic-pyruvic tnmsaminase (GPI), 
and creatinine (Cr) were determined using GOT-UV test, 
Wako, GPTUV test, Wako, and Cr test, Wako (Wake Pure 
Chemical Industries, Osaka, Japan), respectively. Animal 
experiments were performed according to the ethical 
guidelines of the Institute for Laboratory Animal Research, 
Nagoya University School of Medicine. 
Endotoxin Assay 
Endotoxin activity was determined by a specific chro- 
mogenic assay using the Limulus coagulation enzyme (ES 
test). Endotoxin concentrations were calculated by com- 
parison with the reference endotoxin from E. coli 0111 :B4. 
The samples and reference endotoxin were serially diluted 
in endotoxin-free physiologic saline to achieve concen- 
trations in the 0.01 to 0.5 ng/mL range, in which the assay 
gives a linear relation between E. coli endotoxin 0111 :B4 
concentration and spectrophotometric absorbance. 
Statistical Analysis 
Results are expressed as mean ? standard error of the 
mean. Paired data were compared using a two-tailed paired 
t-test; P-values less than 0.05 were considered significant. 
RESULTS 
Antibiotic Susceptibility 
Escherichia coli TCH97-9379 isolate was susceptible 
to ceftazidime (MIC = 1 mg/L), but highly resistant to 
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lincomycin (MIC = 2048 mg/L), and clindamycin 
(MIC = 512 mg/L). 
Antibiotic-Induced Release of Endotoxin In Vitro 
Exposure of E. coli to lincomycin or clindamycm resulted 
in a marked increase in released endotoxin (Figure 1). 
Endotoxin was released more slowly from E. coZi exposed 
to lincomycin than to clindamycin at 8 mg/L. However, 
after 6 hours of exposure there was no difference in the 
levels of endotoxin released by equivalent concentrations 
of lincomycin and clindamycin. Moreover, the lower con- 
centration (8 mg/L) of these antibiotics induced larger 
amounts of endotoxin release than exposure to 0.5 MIC, 
but the difference was not significant (P > 0.05). The 
amounts of endotoxin released after 6 hours of treatment 
with lincomycin and clindamycin were significantly 
smaller than with ceftazidime (P < 0.05). Exposure to 
0.5 MIC of lincomycin, clindamycin, and ceftazidime 
inhibited the growth of E. coli, whereas the cells contin- 
ued to grow in the presence of 8 mg/L of lincomycin or 
clindamycin (see Figure 1). Antibiotics themselves had 
no effect on the Limuhs assay in vitro (data not shown). 
Morphologic Changes Induced by Antibiotics 
Morphologic changes in E. COZY after 0,1.5,3, and 6 hours 
of exposure to 0.5 MIC and 8 mg/L of lincomycin and 
clindamycin were observed by SEM; micrographs at 
3 hours are shown in Figure 2. Ceftazidime, which 
induces filament formation, was used as a control.” Fila- 
mentation had already been observed after 1.5 hours of 
treatment of E. coli with lincomycin, clindamycin, or cef- 
tazidime. More filamentation was induced during 6 hours 
of treatment at 0.5 MIC of all antibiotics, whereas at low 
concentrations (8 mg/L), both bacillary cells (normal 
shape) and filamentous cells increased. After 6 hours of 
treatment with 0.5 MIC of lincomycin or clindamycin, 
more filamentation was observed than with 8 mg/L. The 
magnitude of filamentation induced by 0.5 MIC of lin- 
comycin or clindamycin was lower than that induced by 
ceftazidime. After treatment with lincomycin at 0.5 MIC, 
E. coli sometimes showed bulge formation among fila- 
mentous cells (see Figure 2). 
Endotoxin Release and Its Effects In Vivo 
Plasma endotoxin concentrations in E. coli sepsis rat mod- 
els were 20-fold higher after treatment with lincomycin or 
clindamycin at 5 mg/kg than with no antibiotic (Figure 3). 
There were no significant differences in plasma endotoxin 
concentrations between lincomycin, clindamycin, and cef- 
tazidime treatment (P > 0.05). The increase in plasma 
endotoxin concentrations was associated with a decrease 
in platelet counts (see Figure 3) and an increase in GOT 
values (Table 1). Lincomycin and clindamycin treatment 
decreased the platelet counts to one-third that of controls 
(see Figure 3). There were no significant differences in 
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Figure 1. Effects of lincomycin, clindamycin, and ceftazidime at 0.5 
MIC and 8 mg/L on (A) growth (cfu/mL) and (B) release of endotoxin from 
E. co/i TCH97-9379 (mg/L). Antibiotics were added at time zero: cef- 
tazidime at 0.5 MIC (D, lincomycin at 0.5 MIC (0) lincomycin at 8 mg/L 
(0) clindamycin at 0.5 MIC (A), and clindamycin at 8 mg/L (A); no 
antibiotics (0. Ceftazidime, lincomycin, and clindamycin 0.5 MlCs were 
0.5, 1024, and 256 mg/L, respectively. Free LPS was obtained from 
antibiotic-treated cultures by direct filtration of samples with 0.45~km fil- 
ters. Each figure shows mean data for three separate experiments, 
the platelet counts between treatment with lincomycin, 
clindamycin, and ceftazidime (P > 0.05). The GOT values 
after treatment with lincomycin, clindamycin, or cef- 
tazidime were significantly higher than those of controls 
(P < 0.05) and the GPT and Cr values following treatment 
with lincomycin or ceftazidime were significantly higher 
than those of controls (P < 0.05). There were no differ- 
ences in GOT, GPT, and Cr values between lincomycin-, 
clindamycin-, and ceftazidime-treated rats (P > 0.05). 
Antibiotics themselves had no effect on the Limulus assay 
in vivo (data not shown). 
DISCUSSION 
Lincomycin and clindamycin are used for treatment of 
infections attributable to anaerobic bacteria, but they are 
ineffective against aerobic gram-negative bacteria.20z21 This 
study demonstrates that treatment of E. coli sepsis with 
these antibiotics results in the liberation of high levels of 
endotoxin in vitro and in vivo. The data suggest that the 
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Figure 2. Scanning electron micrographs of E. co/i TCH97-9379 
exposed to antibiotics for 3 hours. Bacteria were treated with A, noth- 
ing; B, ceftazidime at 0.5 MIC; C, lincomycin at 8 mg/L; D, lincomycin 
at 0.5 MIC; E, clindamycin at 8 mg/L; and F, clindamycin at 0.5 MIC. 
Ceftazidime, lincomycin, and clindamycin 0.5 MlCs were 0.5, 1024, and 
256 mg/L, respectively. The arrows indicate a bulged cell. Bar = 3 km. 
administration of these antibiotics as combined or empir- 
ical therapy for patients infected with gram-negative 
bacilli can result in the release of large amounts of 
endotoxin. 
A number of reports have indicated that clinical dete- 
rioration in patients receiving antibiotic therapy for gmm- 
negative sepsis is attributable to an increase in plasma 
endotoxin concentrations.3.9.22-24 The results of this study 
are consistent with those previous observations; the abil- 
ity of lincomycin to release large amounts of endotoxin 
may explain the worsened clinical condition of the 
patient with E. coli sepsis soon after receiving empirical 
lincomycin therapy. 
To date, in vitro studies have shown that the various 
classes of antibiotics differ in the quantity of endotoxin 
released.4,‘~‘J~25 The amount of endotoxin released by 
z No Antibiotic Ceftazidime Lincomycin Clindamycin 
Ill 
Figure 3. Plasma endotoxin concentrations and platelet counts in 
rats after treatment with lincomycin, clindamycin, and ceftazidime. Rats 
were challenged with an intraperitoneal inoculation of 10” cfu of E. co/i 
TCH97-9379 isolate 24 hours prior to intravenous administration of 
antibiotics. H endotoxin released (kg/L); , q platelet count (1 OVpL). 
antibiotic treatment is associated with bacterial morpho- 
logic change: filament formation of gram-negative bacilli 
results in the liberation of large amounts of endotoxin, 
whereas oval formation induces smaller amounts.7~14~‘6~i8 
The results of this study verify this, in that filamentation 
induced by lincomycin and clindamycin was associated 
with high levels of endotoxin release in vitro. The time 
course of endotoxin release did not differ between large 
(0.5 MIC) and small antibiotic doses (8 mg/L) in vitro. 
Therefore, these findings suggest that lincomycin or clin- 
damycin treatment of aerobic gram-negative sepsis, inde- 
pendent of the dose used, is not only ineffective but also 
harmful, because of the liberation of large amounts of 
endotoxin. This differs from the finding that treatment 
with filament-forming @lactams at high doses increases 
bacterial killing and reduces endotoxin release.2” 
To determine liberation of endotoxin in vivo, an E. 
coli sepsis rat model was used. Plasma endotoxin con- 
centrations after treatment with lincomycin or clin- 
damycin were as high as those with ceftazidime, which 
is in agreement with the in vitro data. In vivo data in the 
present study showed that treatment with lincomycin or 
Table 1. Glutamic-Oxaloacetic Transaminase, Glutamic-Pyruvic 
Transaminase, and Creatinine in Rats Treated with Ceftazidime, 
Lincomycin, and Clindamycin Compared to Controls 
Antibiotic GOT (/U/L) GPT (/U/L) 0 (s/L/ 
Ceftazidime 48.8 t 1.22 
;[t+i%ht ~~;~~~~~~~*K~i] %!;!i!~~~* 
Rats were challenged with an intraperitoneal inoculation of 10” cfu of E. co/i 
TCH97-9379 isolate 24 hours prior to intravenous administration of antibiotics. 
GOT = glutamic-oxaloacetic transaminase; GPT = glutamic-pyruvic trans- 
aminase; Cr = creatinine. *P < 0.05. 
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clindamycin for E. colt’ sepsis resulted in liberation of 
great amounts of endotoxin, as well as decreased platelet 
counts and increased GOT values. Although treatment of 
gram-negative bacterial infection with antibiotics that 
induce endotoxin release does not always result in sep- 
tic shock, probably because of various factors influenc- 
ing endotoxin release, &*’ clinicians should be cautious 
in using antibiotics that are likely to induce release of 
large amounts of endotoxin. 
This is believed to be the frost report to demonstrate 
that the bacteriostatic antibiotics, lincomycin and clin- 
datnycin, induce signihcant endotoxin release in vitro and 
in vivo. The results suggest that the antibiotic-induced 
endotoxin release should be taken into account when use 
of these antibiotics is considered for bacterial infections in 
which gram-negative organisms are the likely pathogens. 
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